Early Continuous Glucose Monitoring to Lower the Risk of Gestational Diabetes Mellitus in Women With Pre‐Pregnancy Obesity: Protocol for the Multicentre Randomised Controlled Trial ( GLOW )

Aims Pre‐pregnancy obesity substantially increases the risk of gestational diabetes mellitus ( GDM ), yet preventive strategies before routine GDM screening remain limited. The Glucose monitoring to Lower risk of GDM in Obese pregnant Women ( GLOW ) trial aims to determine whether continuous glucose monitoring ( CGM ) initiated in early pregnancy reduces the incidence of GDM in women with pre‐pregnancy obesity. Materials and Methods GLOW is a national, multicentre, open‐label, parallel‐group randomised controlled trial enrolling 1034 women with pre‐pregnancy body mass index ≥ 28 kg/m 2 , a singleton pregnancy and gestational age ≤ 14 +6 weeks at eight hospitals in China. Participants will be randomised 1:1 to routine antenatal care alone or routine antenatal care plus CGM . In the CGM group, five consecutive 14‐day sensors will be used from 14 +0 –14 +6 to 24 +0 –24 +6 weeks of gestation (70 days in total), with access to glucose values and standardised CGM education. The primary endpoint is the incidence of GDM diagnosed by a 75‐g oral glucose tolerance test at 24 +0 –24 +6 weeks. Secondary outcomes include gestational weight gain, maternal metabolic and anthropometric measures, lifestyle behaviours and maternal and neonatal outcomes. Results and Conclusions GLOW will determine whether early CGM introduced before routine GDM screening can reduce GDM incidence and favourably influence maternal metabolic and pregnancy outcomes in women with pre‐pregnancy obesity. The findings may inform the role of early CGM as a preventive strategy in this high‐risk population. Trial Registration Chinese Clinical Trial Registry: ChiCTR2600130043

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-18
DOI
https://doi.org/10.1111/dom.71563
Primary Topic
Gestational Diabetes Research and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early Continuous Glucose Monitoring to Lower the Risk of Gestational Diabetes Mellitus in Women With Pre‐Pregnancy Obesity: Protocol for the Multicentre Randomised Controlled Trial ( GLOW )

龚云辉, Jianhua Niu, Hongwei Wei, Y. Lu et al.
Diabetes Obesity and Metabolism
Gestational Diabetes Research and Management
article

Early Continuous Glucose Monitoring to Lower the Risk of Gestational Diabetes Mellitus in Women With Pre‐Pregnancy Obesity: Protocol for the Multicentre Randomised Controlled Trial ( GLOW )

龚云辉, Jianhua Niu, Hongwei Wei, Y. Lu, Qiaoling Du, Yang Mi, Jianying Yan, Juan Juan, Zhonghua Shi, Zongyuan Tian, Jie Li, Di Gao, Huixia Yang
article en

Abstract

Aims Pre‐pregnancy obesity substantially increases the risk of gestational diabetes mellitus ( GDM ), yet preventive strategies before routine GDM screening remain limited. The Glucose monitoring to Lower risk of GDM in Obese pregnant Women ( GLOW ) trial aims to determine whether continuous glucose monitoring ( CGM ) initiated in early pregnancy reduces the incidence of GDM in women with pre‐pregnancy obesity. Materials and Methods GLOW is a national, multicentre, open‐label, parallel‐group randomised controlled trial enrolling 1034 women with pre‐pregnancy body mass index ≥ 28 kg/m 2 , a singleton pregnancy and gestational age ≤ 14 +6 weeks at eight hospitals in China. Participants will be randomised 1:1 to routine antenatal care alone or routine antenatal care plus CGM . In the CGM group, five consecutive 14‐day sensors will be used from 14 +0 –14 +6 to 24 +0 –24 +6 weeks of gestation (70 days in total), with access to glucose values and standardised CGM education. The primary endpoint is the incidence of GDM diagnosed by a 75‐g oral glucose tolerance test at 24 +0 –24 +6 weeks. Secondary outcomes include gestational weight gain, maternal metabolic and anthropometric measures, lifestyle behaviours and maternal and neonatal outcomes. Results and Conclusions GLOW will determine whether early CGM introduced before routine GDM screening can reduce GDM incidence and favourably influence maternal metabolic and pregnancy outcomes in women with pre‐pregnancy obesity. The findings may inform the role of early CGM as a preventive strategy in this high‐risk population. Trial Registration Chinese Clinical Trial Registry: ChiCTR2600130043

Diabetes Obesity and Metabolism
Tongji University (CN), Fujian Medical University (CN), Sichuan University (CN), West China Second University Hospital of Sichuan University (CN), Northwest Women's and Children's Hospital (CN), Nanjing Drum Tower Hospital (CN), Guangxi Maternal and Child Health Hospital (CN), Peking University First Hospital (CN), Changzhou No.2 People's Hospital (CN), Shanghai First Maternity and Infant Hospital (CN)
Gestational Diabetes Research and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon